![Jack Troia](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jack Troia
Direttore Finanziario/CFO presso Omnitura Therapeutics, Inc.
Profilo
Jack Troia is currently the Chief Financial Officer at Omnitura Therapeutics, Inc. Prior to this, he worked as the National Director at Deloitte & Touche.
Posizioni attive di Jack Troia
Società | Posizione | Inizio |
---|---|---|
Omnitura Therapeutics, Inc.
![]() Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | Direttore Finanziario/CFO | - |
Precedenti posizioni note di Jack Troia
Società | Posizione | Fine |
---|---|---|
Deloitte & Touche
![]() Deloitte & Touche Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche provides audit, enterprise risk management, and financial advisory services. The company delivers services in four professional areas: audit, tax, consulting, and financial advisory services. It provides its clients with global services such as entering foreign markets, raising funds, and investing in Mainland China. The company was founded in June, 2003 and is headquartered in Taipei, Taiwan. | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Omnitura Therapeutics, Inc.
![]() Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | Health Technology |
Deloitte & Touche
![]() Deloitte & Touche Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche provides audit, enterprise risk management, and financial advisory services. The company delivers services in four professional areas: audit, tax, consulting, and financial advisory services. It provides its clients with global services such as entering foreign markets, raising funds, and investing in Mainland China. The company was founded in June, 2003 and is headquartered in Taipei, Taiwan. | Commercial Services |
- Borsa valori
- Insiders
- Jack Troia